Project Grant R37CA302926
Award Date 7/10/26
Completion Date 6/30/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- Federal Grant Award Summary Oregon Health & Science University received a $401,115 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 10, 2026, with a completion date of June 30, 2028. The award funds development of a patient-derived intestinal organoid system to model gastrointestinal toxicity associated with immune checkpoint inhibitors (ICIs)—monoclonal antibodies targeting PD-1 and CTLA-4 receptors used in cancer...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $2.27 million Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective September 23, 2025, with an anticipated completion date of August 31, 2029. This research initiative investigates the role of androgen receptor (AR) signaling in conventional dendritic cells (CDCs) and its impact on anti-tumor immune function, with particular focus on sex-based...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Oregon Health & Science University a Project Grant of $640,113 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop multifunctional ultrasound-responsive nanoparticles (URNs) for enhanced melanoma immunotherapy. The grant supports a five-year research initiative (completion date May 31, 2031) aimed at addressing the approximately 50% of melanoma patients who do not...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $648,626 to the University of California Irvine on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support a five-year project extending through March 31, 2031. This Project Grant funds fundamental research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Providence Health & Services - Oregon a $1.43M Project Grant under the Cancer Treatment Research program (CFDA 93.395) for a five-year research initiative beginning May 1, 2026. The award supports investigations into spatiotemporal molecular mechanisms of radiation-induced tumor microenvironment remodeling to enhance immunotherapy efficacy in head and neck squamous cell carcinoma (HNSCC). The research builds on promising...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $625,179 Project Grant award dated March 26, 2026, from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct research on MCL1 (myeloid cell leukemia-1) targeting for treatment of lung metastasis in osteosarcoma. The project, which runs through February 28, 2031, will develop and validate innovative therapeutic approaches combining MCL1 inhibitors with conventional...
- Federal Grant Award Summary Oregon Health & Science University received a $1,042,004 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on March 26, 2026, with a completion date of February 28, 2031. The award funds development and validation of a microphysiological bone metastasis-on-a-chip platform designed to advance understanding of prostate cancer metastasis to bone, which occurs in over 80% of advanced prostate cancer...
- Federal Project Grant Award Summary Award Details: Oregon Health & Science University received a $356,850 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. The award supports research focused on developing a novel therapeutic approach to overcome chemoresistance in ovarian cancer by targeting Y-Box Binding Protein 1 (YB-1). Scope of Work: The project investigates SU056, a...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...